Dr Jorrit Lemkes (Amsterdam University Medical Center, the Netherlands) presented the 1-year follow-up data from the Coronary Angiography after Cardiac Arrest (COACT) trial [1], which was the first randomised trial in cardiac arrest patients without STE investigating whether immediate angiography could improve survival and major adverse cardiac events at 1 year, as opposed to a delayed invasive strategy. This open-label, multicentre trial enrolled 552 OHCA patients who were allocated to receive either immediate angiography (n=264) or delayed angiography (n=258).
Survival at 90 days was the primary endpoint. Secondary endpoints included survival at 90 days with good cerebral performance or moderate disability, thrombolysis in myocardial infarction major bleeding, recurrence of ventricular tachycardia, occurrence of acute kidney injury and need for renal-replacement therapy, time-to-target temperature, duration of inotropic/catecholamine support, duration of mechanical ventilation, myocardial injury, and markers of shock.
The results did not indicate significant improvement with immediate angiography; 1-year survival outcomes were 61.4% of patients in the immediate angiography group and 64.0% of patients in the delayed group (OR 0.90; 95% CI 0.63-1.28). Additionally, no significant differences were observed in the rates of myocardial infarction, revascularisation, hospitalisation due to heart failure, or implantable cardioverter defibrillator (ICD) shocks between the 2 treatment groups at 1 year. These results do not support a strategy of immediate angiography with intent to revascularise for patients with resuscitated OHCA without STE.
1. Lemkes J, et al. One Year Outcomes of Coronary Angiography After Cardiac Arrest. LBS04, AHA Scientific Sessions 2019, 14-18 November, Philadelphia, USA.
Posted on
Previous Article
« Early apixaban safe as secondary prevention of stroke from AF Next Article
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients »
« Early apixaban safe as secondary prevention of stroke from AF Next Article
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients »
Table of Contents: AHA 2019
Featured articles
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint
Inclisiran safely halves LDL-Cholesterol
Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves
RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies
New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Carvedilol does not improve exercise performance in Fontan patients
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Related Articles
February 26, 2020
Early apixaban safe as secondary prevention of stroke from AF
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com